Back to search
FDAFDA · Food and drugs·Recall number D-0651-2024

Tirzepatide 2 mL (10 mg/mL) and 20 mg/mL, 2mL Multidose SC Injection vials, Compounded Rx Product, ProRx 267-565-7008, NDC 84139-210-01

Published September 11, 2024 · Recall initiated: August 22, 2024

Summary

FDA records drug Class II recall D-0651-2024, published September 11, 2024 and initiated August 22, 2024. Recalling firm: ProRx LLC; Status: Ongoing; Reported quantity: 37 vials; Lot: Lot # ProRx040924-1, BUD 10/08/2024. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Lack of Assurance of Sterility

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
ProRx LLC
Distributor
Nationwide in the USA
Lot
Lot # ProRx040924-1, BUD 10/08/2024
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Tirzepatide 2 mL (10 mg/mL) and 20 mg/mL, 2mL Multidose SC Injection vials, Compounded Rx Product, ProRx 267-565-7008, NDC 84139-210-01 recalled?

Yes. FDA published recall D-0651-2024 on September 11, 2024. Reported hazard: Lack of Assurance of Sterility

What should I do if I have this product?

Voluntary: Firm initiated · Letter